Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Russo

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Tumori|December 24, 2016
Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patientsGiulia Marvaso, Barbara A Jereczek-Fossa, Barbara Vischioni, et al.
Tumori|August 13, 2016
Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesionGiorgia Timon, Delia Ciardo, Alessia Bazani, et al.
Frontiers in Oncology|December 6, 2021
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300Giulia Marvaso, Barbara Vischioni, Matteo Pepa, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Clinical Breast Cancer|December 26, 2018
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective StudySara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Tumori|December 24, 2016
Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patientsGiulia Marvaso, Barbara A Jereczek-Fossa, Barbara Vischioni, et al.
Tumori|August 13, 2016
Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesionGiorgia Timon, Delia Ciardo, Alessia Bazani, et al.
Frontiers in Oncology|December 6, 2021
Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300Giulia Marvaso, Barbara Vischioni, Matteo Pepa, et al.
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Nature|September 6, 2023
Spatial predictors of immunotherapy response in triple-negative breast cancerXiao Qian Wang, Esther Danenberg, Chiun-Sheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Clinical Breast Cancer|December 26, 2018
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective StudySara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, et al.
Pageof 9